Biothera

110 articles about Biothera

• HiberCell Announces Acquisition of Biothera Pharmaceuticals' Imprime PGG Program

  7/7/2020

  - Imprime PGG, a novel immune activator, has undergone rigorous Phase II testing for the treatment of metastatic breast cancer - Biothera president and chief scientific officer, Jeremy R. Graff, Ph.D., will assume the role of chief development officer at HiberCell

• Biothera Pharmaceuticals Presents Updated Phase 2 Data for Chemo-refractory Triple Negative Breast Cancer Patients at San Antonio Breast Cancer Symposium

  12/11/2019

  The study is evaluating Biothera’s Imprime PGG, a systemically delivered dectin receptor agonist that triggers anti-cancer immune responses, in combination with Merck’s anti-PD-1 therapy, KEYTRUDA®

• Biothera Pharmaceuticals Enters Cancer Immunotherapy Clinical Trial Collaboration Agreement

  11/28/2017

  Phase 1b/2 clinical study in colorectal cancer to evaluate Imprime PGG in combination with PD-L1 immunotherapy and anti-VEGF therapy.

• Biothera Pharmaceuticals Presents Data Broadening Imprime PGG Mechanism of Action

  11/13/2017

  The data were presented at the Society for Immunotherapy of Cancer (SITC) annual meeting.

• Biothera Pharmaceuticals Presents Preclinical Data Showing Imprime PGG Activates Natural Killer Cell-Mediated Tumor Killing

  10/30/2017

  The data will be presented at the AACR-NCI-EORTC International Conference.

• Biothera Announces Initiation Of Phase Ib/II Clinical Study Evaluating Combination Of Imprime PGG And Merck & Co.’s KEYTRUDA In Non-Small Cell Lung Cancer

  7/19/2017

• Biothera’s Phase II Study Of Imprime PGG Combination Therapy In Non-Small Cell Lung Cancer Patients Published In Investigational New Drugs

  3/27/2017

• Biothera Announces Presentation Of Clinical Data Supporting Use Of A Patient Selection Biomarker For Its Phase II Cancer Immunotherapy

  2/27/2017

• Biothera Announces Data Demonstrating Unique Immune Response Profile Generated By Phase 2 Cancer Immunotherapy Imprime PGG

  11/30/2016

• Biothera Preclinical Data Further Validate Mechanism Of Its Phase II Cancer Immunotherapy, Imprime PGG

  11/11/2016

• Clinical Data Support Mechanism Of Action And Patient Selection Biomarker For Imprime PGG, Biothera's Phase II Cancer Immunotherapy

  9/27/2016

• Biothera Expands Relationship With Merck & Co., Enters Collaboration For Combination Cancer Immunotherapy Trials In Multiple Indications

  8/24/2016

• Biothera To Present At The Canaccord Genuity Growth Conference

  8/3/2016

• Biothera Presents New Cancer Immunotherapy Research At The 2016 AACR Annual Meeting

  4/19/2016

• Biothera Announces Presentations at Upcoming AACR Annual Meeting

  3/17/2016

• Biothera Announces Imprime PGG Positive Safety Findings And Pharmacokinetic Data From Two Phase 1 Studies, As Published In Investigational New Drugs: The Journal Of New Anticancer Agents

  2/25/2016

• Biothera’s Imprime PGG And Anti-Angiogenic Antibodies Work In Concert To Re-Orient The Immune Microenvironment To Support Cancer Killing, Study Finds

  11/6/2015

• Biothera's Imprime PGG And Monoclonal Antibody Therapy Alleviates Immune Suppression In Tumor Microenvironment And Increases Cancer Cell Killing

  11/6/2015

• Biothera To Present Three Abstracts At AACR-National Cancer Institute-EORTC International Conference On Molecular Targets And Cancer Therapeutics

  11/2/2015

• Biothera Appoints Dr. Jose Iglesias As Chief Medical Officer

  10/15/2015